Freiburg ZNS-NHL study: Therapy for patients with primary non-Hodgkin lymphoma of the CNS [central nervous system]-sequential high dosage chemotherapy with autologous peripheral blood stem cell transplantation.

Trial Profile

Freiburg ZNS-NHL study: Therapy for patients with primary non-Hodgkin lymphoma of the CNS [central nervous system]-sequential high dosage chemotherapy with autologous peripheral blood stem cell transplantation.

Completed
Phase of Trial: Phase II

Latest Information Update: 30 Jun 2017

At a glance

  • Drugs Carmustine (Primary) ; Cytarabine (Primary) ; Rituximab (Primary) ; Thiotepa (Primary) ; Methotrexate
  • Indications Non-Hodgkin's lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 06 Dec 2016 Results presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
    • 02 Mar 2013 New source identified and integrated (European Clinical Trials Database: EudraCT2005-000615-99).
    • 06 Jun 2012 New source identified and integrated (German Clinical Trials Register; DRKS00003748).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top